Catalog No.
RVV00324
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
Receptor-Binding Domain, RBD, Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, S
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P0DTC2
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
H11-D4
Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants., PMID:40329514
Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2., PMID:40317451
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243
The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2., PMID:40136472
Computational electrostatic engineering of nanobodies for enhanced SARS-CoV-2 receptor binding domain recognition., PMID:40129869
Engineering Genome-Free Bacterial Cells for Effective SARS-COV-2 Neutralisation., PMID:40042439
Novel nanobody drug conjugate as a prophylactic or therapeutic against SARS-CoV-2 infection in mice., PMID:39970838
A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548
Pharmacoinformatics-based screening and construction of a neutralizing anti-SARS-CoV-2 camelidae nanobody drug conjugate., PMID:39873888
Visual and High-Efficiency Secretion of SARS-CoV-2 Nanobodies with Escherichia coli., PMID:39858505
Development of a Nanobody-Alkaline Phosphatase Fusion Protein for Detection of SARS-CoV-2 Spike Protein in a Fluorescence Enzyme Immunoassay., PMID:39699064
Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant., PMID:39675603
Facilitating and restraining virus infection using cell-attachable soluble viral receptors., PMID:39480852
Identification of a potent SARS-CoV-2 neutralizing nanobody targeting the receptor-binding domain of the spike protein., PMID:39383917
Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody., PMID:39366179
Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics., PMID:39356775
Nanomechanical footprint of SARS-CoV-2 variants in complex with a potent nanobody by molecular simulations., PMID:39351797
Structure-guided in vitro evolution of nanobodies targeting new viral variants., PMID:39325826
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain., PMID:39218023
Nanobody-based strategy for rapid and accurate pathogen detection: A case of COVID-19 testing., PMID:39094292
A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation., PMID:38939869
Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants., PMID:38920116
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses., PMID:38822339
Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain., PMID:38740785
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD., PMID:38692413
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1., PMID:38675799
A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant., PMID:38501378
Polyvalent Nanobody Structure Designed for Boosting SARS-CoV-2 Inhibition., PMID:38408177
Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies., PMID:38400113
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice., PMID:38399961
Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries., PMID:38350843
Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2., PMID:38341574
Therapeutic antibodies and alternative formats against SARS-CoV-2., PMID:38307147
A Portable and Disposable Electrochemical Sensor Utilizing Laser-Scribed Graphene for Rapid SARS-CoV-2 Detection., PMID:38248387
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters., PMID:38065245
Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization., PMID:38033141
Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein., PMID:38000614
A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein., PMID:37984151
Plant virus-derived nanoparticles decorated with genetically encoded SARS-CoV-2 nanobodies display enhanced neutralizing activity., PMID:37966715
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains., PMID:37901798
Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252., PMID:37896913
Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2., PMID:37874836
A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern., PMID:37869063
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2., PMID:37863812
SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain., PMID:37726484
Binding of synthetic nanobodies to the SARS-CoV-2 receptor-binding domain: the importance of salt bridges., PMID:37655617
The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein., PMID:37464199
Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models., PMID:37423308
Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes., PMID:37419228
For research use only. Not for human or drug use.
